MORPHOSYS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 66.1 EUR | -0.15% |
|
-2.44% | +94.41% |
| Apr. 30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
| Apr. 30 | MorphoSys AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 249M 267M | Sales 2025 * | 325M 349M | Capitalization | 2.49B 2.67B |
|---|---|---|---|---|---|
| Net income 2024 * | -430M -462M | Net income 2025 * | -116M -125M | EV / Sales 2024 * | 10.4 x |
| Net Debt 2024 * | 89.28M 95.83M | Net cash position 2025 * | 94.69M 102M | EV / Sales 2025 * | 7.36 x |
| P/E ratio 2024 * |
-5.85
x | P/E ratio 2025 * |
-31.7
x | Employees | 524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on MorphoSys AG
More recommendations
More press releases
More news
| 1 day | -0.15% | ||
| 1 week | -2.44% | ||
| Current month | -1.64% | ||
| 1 month | -1.71% | ||
| 3 months | +65.33% | ||
| 6 months | +121.44% | ||
| Current year | +94.41% |
1 week
65.20
67.85
1 month
65.2068.00
Current year
29.7368.00
1 year
14.5268.00
3 years
11.8180.14
5 years
11.81146.30
10 years
11.81146.30
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 19-08-31 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 23-08-06 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 18-05-16 |
| Director/Board Member | 67 | 18-05-16 | |
Marc Cluzel
CHM | Chairman | 69 | 12-05-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.44% | 125 M€ | -.--% | ||
| 0.80% | 17 M€ | -.--% | - | |
| 0.11% | 2 M€ | -.--% | ||
| 0.02% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 66.1 | -0.15% | 313,371 |
| 24-04-30 | 66.2 | +0.84% | 357,848 |
| 24-04-29 | 65.65 | -3.24% | 1,203,894 |
| 24-04-26 | 67.85 | +0.15% | 39,191 |
| 24-04-25 | 67.75 | +0.07% | 56,527 |
Delayed Quote Xetra, May 02, 2024 at 11:35 am EDT
More quotes
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
66.1
EUR
Average target price
58.71
EUR
Spread / Average Target
-11.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +94.41% | 2.66B | |
| +26.28% | 42.68B | |
| -3.99% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +6.36% | 24.94B | |
| -21.47% | 18.96B | |
| +27.58% | 12.3B | |
| -2.75% | 11.95B | |
| -2.02% | 11.55B |
- Stock Market
- Equities
- MOR Stock
